regulatory submission

Actionable Insights Powered by AI

Lilly’s Q2 2025 Beat-and-Raise Overshadowed by Orforglipron Data

Eli Lilly; Q2 2025 earnings; orforglipron; oral GLP-1; weight loss; obesity franchise; regulatory submission; analyst expectations